BORTEZOMIB: AN ANTI-PROTEASOMAL AGENT

by Selleckchem | Jul 01 2012

BORTEZOMIB: INTRODUCTION
In cell among the tiny organelles proteasomes are the foremost vital ones. They play necessary role in the correct regulation of the cell cycle by removing the proteins that don't seem to be necessary for cell. In cancer cell it rarely happens that the proteins which are involved in the controlling the dysregulated growth of the cells are excised by proteasomes. A promising target for the therapy of cancer is to inhibit proteasomes so that the uncontrolled growth is inhibited. A variety of compounds were typically used for cancer therapy that inhibits proteasomes. Among them EGCG additionally referred to as Epigallocatechin-3-gallate, Disulfiram and Salinosporamide-A that are present in green tea were used. The primary inhibitor of proteasomes that got approved to enter clinical trials for cancer therapy is Bortezomib.
Proteasome is inhibited by boranate inhibitor that is Bortezomib and it's terribly precise in its action by specifically targeting the compound. It is commercially in the market as either Velcadeor Bortezomib PS-34. The primary proteasomal inhibitor was this that entered the clinical trials of patients affected by multiple bone marrow cancer cells. The studies of Bortezomib structure revealed that it contains boric acid and this boron atom is assumed to be terribly active in its action. Every 1000mg of vial is approximately of $2000 that is offered for researchers who want to buy Bortezomib. Different Bortezomib supplier offer different Bortezomib price. Around 200 mg/ml of dimethyl sulfoxide (DMSO) is appropriate for Bortezomib solubility since it insoluble in water. Quite effective results are obtained by using Bortezomib IC50 that is 10nM.

BORTEZOMIB: MODE OF ACTION
Several types of cancers have shown very active response on the administration of Bortezomib proteasome inhibitor. The vital role in communication between proteasome and the drug is played by boron atoms. Bortezomib aims specifically cancer cells due to the occurrence of binding sites in them. It doesn’t interact and affect the normal cells [1]. The multidrug resistance due to the Bortezomib was seen alterable in cell lines of lymphoma and leukemia by doing a point mutation in proteasomeβ5 G322A in subunit [2]. So the way of action of this medicine can be inferred from this study. In renal neoplastic cells its persistence and proliferation is controlled by NF-kB pathway it was seen inhibited ultimately causing cell death by the process of apoptosis [3]. Bortezomib’ mode of action was also studied in vitro in cancer cell lines of prostate cancer and in vivo by studying it in human cancer cells of bladder/prostate. In earlier cells lines it was found to stop the NF-kB cascade by causing the apoptosis either with the help of tumor necrosis factor (TNF) in TRIAL pathway [5] or in other cell lines by up regulating p21 gene.

BORTEZOMIB: CLINICAL TRIALS
The pharmacokinetic studies of Bortezomib showed that it is speedily cleaned from body if it is injected post-intravenously [6]. Results of these conclusions led to clinical trials initiation. After studying the genetic expression profiles of lymphoma patients of phase II and as well as phase III trials the efficiency and safety of Bortezomib was seen exceptional [7]. The assessment studies on the frequency of relapsed patients of clinical trials phase II was done before this profiling was conducted [8]. Its effect has also been estimated in prostate cancer cell lines of phase I trials [9]. Its sole effect has been studied in myeloma cells but it’s found to be more effective if it is co-administered with other VEGF inhibitor, arsenic trioxide or thalidomide [11-12]. The co-administration has synergistic effect on myeloma cell lines [13]. Similar varieties of studies have also being done on the effect of co-administration of Bortezomib with histone deacetylases (HDACs) on cell lines of pancreas [14] and with Celecoxib on glioma cancer cell lines [15].

REFERENCES:
1. Rajkumar, S.V.e.a., Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. Journal of Clinical Oncology, 2005. 23(3): p. 630-63.
2. Lü, S.e.a., Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line. Journal of Pharmacology and Experimental Therapeutics, 2008. 326(2): p. 423-431.
3. An, J.e.a., VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kB-dependent mechanism. Oncogene, 2005. 24: p. 1563-1570.
4. Lashinger, L.M.e.a., Bortezomib Abolishes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance via a p21-Dependent Mechanism in Human Bladder and Prostate Cancer Cells. Cancer Res, 2005. 65: p. 4902.
5. Nikrad, M.e.a., The proteasome inhibitor Bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther, 2005. 4: p. 443.
6. Voorhees, P.M.e.a., The proteasome as a target for cancer therapy. Clin Cancer Res, 2003. 9(17): p. 6316-25.
7. Mulligan, G.e.a., Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor Bortezomib. Blood, 2007. 109: p. 3177-3188.
8. Fisher, R.I.e.a., Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology, 2006 24(30): p. 4867-4874.
9. Papandreou, C.N.e.a., Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2004. 22(11): p. 2108-2121.
10. Reeder, C.B.e.a., Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 2009. 23: p. 1337-1341.
11. Anargyrou, K.e.a., Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma, 2008. 49(4): p. 677-689.
12. Richardson, P.G.e.a., Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol, 2005. 18(4): p. 619-634.
13. Nawrocki, S.T.e.a., Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res, 2005. 65(24): p. 11658-11666.
14. Nawrocki, S.T.e.a., Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res, 2006. 66(7): p. 3773-3781.
15. Kardosh, A.e.a., Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res, 2008. 68(3): p. 843-851.